Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Personal Genome Diagnostics Inc.

www.personalgenome.com

Latest From NanoSystems LLC

Inhale Chooses the Service Path

Drug delivery has seen plenty of acquisitions-but they represent two basic philosophical approaches, represented most recently by Johnson & Johnson's purchase of Alza and Inhale's acquisition of two privately-held firms, Bradford and Shearwater. The basic question: can a service model bring significant returns to a large shareholder base or will Alza's evolution into a product company define the way forward for the industry?
BioPharmaceutical Business Strategies

Skyepharma:Trying To Take Off From a Short Runway

Since 1998, through a series of inexpensive acquisitions, SkyePharma has assembled a wide range of drug delivery technologies, positioning itself as a one stop shop. But the company still has to convince both its customers, and its investors, that it has not sacrificed quality for quantity.
BioPharmaceutical Strategy

Inhalable Drug Delivery

Over the past few years, the drug delivery industry has seen a major change in its basic structure. Nowhere is this more true than in the subsegment of inhalable drug delivery. One of the big drivers of the change: drug delivery companies angling for market share in partnering.
BioPharmaceutical Business Strategies

Why the Drug Delivery Industry Can Consolidate

Drug delivery companies have been consolidating with a fury over the last twelve months, unlike biotechs. The difference: delivery firms have plenty of drug service companies to sell to (other drug delivery firms, distributors, generic houses), while biotechs can only sell to Big Pharma--which doesn't want to buy them.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Services
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Personal Genome Diagnostics Inc.
  • Senior Management
  • Douglas Ward, CEO
    Bill Stevens, CFO
    Victor Velculescu, MD, PhD, CSO
    Luis Diaz, MD, CMO
    Jeffrey Boschwitz, PhD, COO
  • Contact Info
  • Personal Genome Diagnostics Inc.
    Phone: (443) 602-8833
    2809 Boston St.
    Ste. 503
    Baltimore, MD 21224
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register